Somewhat Positive Press Coverage Somewhat Unlikely to Impact Pacira Pharmaceuticals (PCRX) Share Price
News headlines about Pacira Pharmaceuticals (NASDAQ:PCRX) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pacira Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.7475606584947 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s rankings:
- Contrasting Dr. Reddy’s Laboratories (RDY) and Pacira Pharmaceuticals (PCRX) (americanbankingnews.com)
- Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc … (prnewswire.com)
- Pacira Pharmaceuticals (PCRX) PT Set at $42.00 by Canaccord Genuity (americanbankingnews.com)
- Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc. on Innovative Collaboration to … – Markets Insider (markets.businessinsider.com)
- Pacira Pharmaceuticals, Inc. (PCRX) Given Average Rating of “Hold” by Brokerages (americanbankingnews.com)
Several research analysts have weighed in on the company. Canaccord Genuity set a $42.00 target price on Pacira Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 29th. Mizuho lowered Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $53.00 to $44.00 in a research report on Wednesday, November 29th. Wedbush reaffirmed a “buy” rating and issued a $80.00 target price on shares of Pacira Pharmaceuticals in a research report on Monday, November 20th. Janney Montgomery Scott set a $27.00 price target on Pacira Pharmaceuticals and gave the stock a “sell” rating in a research note on Thursday, November 16th. Finally, Oppenheimer reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $48.86.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. During the same quarter in the prior year, the company posted $0.20 EPS. The firm’s revenue was down 1.6% on a year-over-year basis. sell-side analysts predict that Pacira Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.
In related news, CAO Kristen Marie Williams sold 10,000 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief accounting officer now owns 23,455 shares in the company, valued at approximately $938,200. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark A. Kronenfeld bought 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average price of $41.60 per share, with a total value of $41,600.00. Following the purchase, the director now owns 6,795 shares in the company, valued at $282,672. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 69,735 shares of company stock valued at $2,692,594. 6.60% of the stock is owned by corporate insiders.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.